ストックスクリーナーアプリを入手
129.16
0.02%
-0.02
アフターアワーズ：
128.50
-0.66
-0.51%
前日終値:
$129.18
開ける：
$130.09
24時間の取引高:
13.41M
Relative Volume:
2.14
時価総額：
$160.36B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
17.57
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-3.92%
1か月 パフォーマンス:
-3.24%
6か月 パフォーマンス:
+6.55%
1年 パフォーマンス:
+16.93%
1日の値動き範囲:
$128.92
$131.66
1週間の範囲:
$127.07
$133.99
52週間の値動き範囲:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.16 | 160.39B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Yahoo Finance
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Harvest Fund Management Co. Ltd Acquires 13,385 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Prudential PLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
GILD: Gilead Supports South Africa's Launch of Lenacapavir for H - GuruFocus
Gilead applauds efforts to launch lenacapavir for HIV prevention in South Africa - The Pharma Letter
Daiwa Securities Group Inc. Has $40.43 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cibc World Market Inc. Buys 97,779 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $2.38 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - Business Wire
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
US FDA approves Gilead's drug for deadly liver infection - MSN
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - TradingView
Gilead Sciences (GILD) Has an HIV-and-Oncology Bridge That Makes the Base Business Harder to Ignore - AlphaStreet
Gilead and Lakefront complete Ouro Medicines acquisition - Investing.com
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - The Manila Times
Gilead’s Livdelzi approved by NICE for PBC - The Pharma Letter
TD Asset Management Inc Sells 67,251 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead eyes PBC expansion for Livdelzi on positive one-year data - Clinical Trials Arena
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
GILD Reports Positive Results From Late-Stage Liver Disease Study - Yahoo Finance
With Cencora pact, Gilead looks to grow CAR-T treatment center network - Fierce Pharma
IDEAL Data Expands Gilead’s Livdelzi Evidence Into Lower-ALP PBC Population - Citeline News & Insights
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Gilead Data On Livdelzi And Trodelvy Points To Broader Future Mix - simplywall.st
Marble Wealth LLC Acquires Shares of 9,588 Gilead Sciences, Inc. $GILD - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Asset Management Inc Buys 128,992 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Bio - GuruFocus
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 15,000 Shares - MarketBeat
Gilead (GILD) CEO Daniel O'Day sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Benzinga
Positive Phase III trial results for Gilead’s Livdelzi - The Pharma Letter
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population - Fierce Pharma
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis - Insider Monkey
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety - Yahoo Finance
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - BioSpace
GILD Sees Positive Phase 3 Results for Livdelzi in Treating Prim - GuruFocus
Gilead reports positive Phase 3 trial results for PBC drug - Investing.com
Thompson Siegel & Walmsley LLC Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks - Barchart.com
Royal Bank Of Canada Upgrades Gilead Sciences (NASDAQ:GILD) to Moderate Buy - MarketBeat
BNP Paribas Has $11.36 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
1.81%
大文字化:
|
ボリューム (24 時間):